Current Awareness

You have free access to this content

Current Awareness in Contrast Media and Molecular Imaging

Article first published online: 28 JAN 2008

DOI: 10.1002/cmmi.154

Issue

Contrast Media & Molecular Imaging

Contrast Media & Molecular Imaging

Special Issue: CONTRAST MEDIA RESEARCH – CMR 2007

Volume 2, Issue 6, pages 305–312, November/December 2007

Additional Information

How to Cite

(2007), Current Awareness in Contrast Media and Molecular Imaging. Contrast Media Mol Imaging, 2: 305–312. doi: 10.1002/cmmi.154

Publication History

  1. Issue published online: 28 JAN 2008
  2. Article first published online: 28 JAN 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (162K)

Current Awareness

  • 1. Reviews
  • Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T, Scarabino T. Proton MR spectroscopy of the brain at 3 T: An update. Eur Radiol 17, 1651-1662 (2007)
  • Dietrich CF, Schreiber-Dietrich D, Schuessler G, Ignee A. Contrast enhanced ultrasound of the liver - State of the art (German, English Abstract). Dtsch Med Wochenschr 132, 1225-1231 (2007)
  • Jackson A, O'Connor JPB, Parker GJM, Jayson GC. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13, 3449-3459 (2007)
  • Jagannathan NR. Molecular imaging in biomedical research. Curr Sci 92, 1061-1069 (2007)
  • Joshi U, Raijmakers PGHM, Riphagen II, Teule GJJ, Van Lingen A, Hoekstra OS. Attenuation-corrected vs. nonattenuation-corrected 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography in oncology: A systematic review. Mol Imaging Biol 9, 99-105 (2007)
  • Kemp GJ, Meyerspeer M, Moser E. Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by 31P MRS: A quantitative review. NMR Biomed 20, 555-565 (2007)
  • Kim D, Hong KS, Song J. The present status of cell tracking methods in animal models using magnetic resonance imaging technology. Mol Cells 23, 132-137 (2007)
  • Lin SP, Brown JJ. MR contrast agents: Physical and pharmacologic basics. J Magn Reson Imaging 25, 884-899 (2007)
  • Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, Krohn KA. Tumor-specific positron emission tomography Imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 13, 3460-3469 (2007)
  • Olszewski R, Timperley J, Szmigielski C, Monaghan M, Nihoyannopoulis P, Senior R, Becher H. The clinical applications of contrast echocardiography. Eur J Echocardiogr 8, S13-S23 (2007)
  • Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Fausto A, Canevari S. Abnormal choline phospholipid metabolism in breast and ovary cancer: Molecular bases for noninvasive imaging approaches. Curr Med Imaging Rev 3, 123-137 (2007)
  • Rakhit DJ, Becher H, Monaghan M, Nihoyannopoulis P, Senior R. The clinical applications of myocardial contrast echocardiography. Eur J Echocardiogr 8, S24-S29 (2007)
  • Selenko P, Wagner G. Looking into live cells with in-cell NMR spectroscopy. J Struct Biol 158, 244-253 (2007)
  • Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 115, 2076-2086 (2007)
  • Vohringer M, Mahrholdt H, Yilmaz A, Sechtem U. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz 32, 129-137 (2007)
  • Wang L, O'Donoghue MB, Tan WH. Nanoparticles for multiplex diagnostics and imaging. Nanomedicine 1, 413-426 (2006)
  • Wester HJ. Nuclear imaging probes: From bench to bedside. Clin Cancer Res 13, 3470-3481 (2007)
  • Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: Theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 3, 91-107 (2007)
  • 2. General
  • Catalano O, Migaleddu V, Quaia E, Caruso G. Terminology for contrast-enhanced sonography - A practical glossary. J Ultrasound Med 26, 717-730 (2007)
  • Nutt R, Vento LJ, Ridinger MHT. In vivo molecular imaging biomarkers: Clinical pharmacology's new “PET”?. Clin Pharmacol Ther 81, 792-795 (2007)
  • Contrast Agents: 3. Chemistry
  • Battistini E, Mortillaro A, Aime S, Peters JA. Molecular recognition of sugars by lanthanide (III) complexes of a conjugate of N,N-bis[2-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]ethyl]glycine and phenylboronic acid. Contrast Media Mol Imaging 2, 163-171 (2007)
  • Bridot JL, Faure AC, Laurent S, Riviere C, Billotey C, Hiba B, Janier M, Josserand V, Coll JL, Vander Elst L, Muller R, Roux S, Perriat P, Tillement O. Hybrid gadolinium oxide nanoparticles: Multimodal contrast agents for in vivo imaging. J Am Chem Soc 129, 5076-5084 (2007)
  • Fu YJ, Raatschen HJ, Nitecki DE, Wendland MF, Novikov V, Fournier LS, Cyran C, Rogut V, Shames DM, Brasch RC. Cascade polymeric MRI contrast media derived from poly(ethylene glycol) cores: Initial syntheses and characterizations. Biomacromolecules 8, 1519-1529 (2007)
  • Horak D, Babic M, Jendelova P, Herynek V, Trchova M, Pientka Z, Pollert E, Hajek M, Sykova E. D-Mannose-modified iron oxide nanoparticles for stem cell labeling. Bioconjug Chem 18, 635-644 (2007)
  • Kim IB, Shin H, Garcia AJ, Bunz UHF. Use of a folate-PPE conjugate to image cancer cells in vitro. Bioconjug Chem 18, 815-820 (2007)
  • Kumagai M, Imai Y, Nakamura T, Yamasaki Y, Sekino M, Ueno S, Hanaoka K, Kikuchi K, Nagano T, Kaneko E, Shimokado K, Kataoka K. Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging. Colloid Surface B 56, 174-181 (2007)
  • Laurent S, Parac-Vogt TN, Kimpe K, Thirifays C, Binnemans K, Muller RN, Vander Elst L. Bis(phenylethylamide)derivatives of Gd-DTPA as potential receptor-specific MRI contrast agents. Eur J Inorg Chem 2061-2067 (2007)
  • Lepage M, Jiang JQ, Babin J, Qi B, Tremblay L, Zhao Y. MRI observation of the light-induced release of contrast agent from photo-controllable polymer micelles. Phys Med Biol 52, N249-N255 (2007)
  • Noestheden M, Hu QY, Tay LL, Tonary AM, Stolow A, MacKenzie R, Tanha J, Pezacki JP. Synthesis and characterization of CN-modified protein analogues as potential vibrational contrast agents. Bioorg Chem 35, 284-293 (2007)
  • Pollet R, Marx D. Ab initio simulation of a gadolinium-based magnetic resonance imaging contrast agent in aqueous solution. J Chem Phys 126, 181102 (2007)
  • Rieter WJ, Kim JS, Taylor KML, An HY, Lin WL, Tarrant T, Lin WB. Hybrid silica nanoparticles for multimodal imaging. Angew Chem Int Ed 46, 3680-3682 (2007)
  • Roh KH, Yoshida M, Lahann J. Water-stable biphasic nanocolloids with potential use as anisotropic imaging probes. Langmuir 23, 5683-5688 (2007)
  • Tesauro D, Accardo A, Gianolio E, Paduano L, Teixeira J, Schillen K, Aime S, Morelli G. Peptide derivatized lamellar aggregates as target-specific MRI contrast agents. Chembiochem 8, 950-955 (2007)
  • Yoo B, Pagel MD. Peptidyl molecular imaging contrast agents using a new solid-phase peptide synthesis approach. Bioconjug Chem 18, 903-911 (2007)
  • Yu G, Yamashita M, Aoshima K, Takahashi M, Oshikawa T, Takayanagi H, Laurent S, Burtea C, Vander Elst L, Muller RN. A glycosylated complex of gadolinium, a new potential contrast agent for magnetic resonance angiography?. Bioorg Med Chem Lett 17, 2246-2249 (2007)
  • Zhang J, Liu KM, Xing GM, Ren TX, Wang SK. Synthesis and in vivo study of metallofullerene based MRI contrast agent. J Radioanal Nucl Chem 272, 605-609 (2007)
  • 4. Technique
  • Alonso A, Della Martina A, Stroick M, Fatar M, Griebe M, Pochon S, Schneider M, Hennerici M, Allemann E, Meairs S. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 38, 1508-1514 (2007)
  • Barmeyer AA, Stork A, Muellerleile K, Tiburtius C, Schofer AK, Heitzer TA, Hofmann T, Adam G, Meinertz T, Lund GK. Contrast-enhanced cardiac MR imaging in the detection of reduced coronary flow velocity reserve. Radiology 243, 377-385 (2007)
  • Bokacheva L, Rusinek H, Chen Q, Oesingmann N, Prince C, Kaur M, Kramer E, Lee VS. Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies. Magn Reson Med 57, 1012-1018 (2007)
  • De Jong N, Emmer M, Chin CT, Bouakaz A, Mastik F, Lohse D, Versluis M. “Compression-only” behavior of phospholipid-coated contrast bubbles. Ultrasound Med Biol 33, 653-656 (2007)
  • Dharmakumar R, Koktzoglou I, Li DB. Factors influencing fast low angle positive contrast steady-state free precession (FLAPS) magnetic resonance imaging. Phys Med Biol 52, 3261-3272 (2007)
  • Diekmann F, Sommer A, Lawaczeck R, Diekmann S, Pietsch H, Speck U, Hamm B, Bick U. Contrast-to-noise ratios of different elements in digital mammography - Evaluation of their potential as new contrast agents. Invest Radiol 42, 319-325 (2007)
  • Du J, Fain SB, Korosec FR, Grist TM, Mistretta CA. Time-resolved contrast-enhanced carotid imaging using undersampled projection reconstruction acquisition. J Magn Reson Imaging 25, 1093-1099 (2007)
  • Ganguly A, Gold GE, Butts Pauly K, Mayer D, Moseley MM, Pelc NJ, Fahrig R. Quantitative evaluation of the relaxivity effects of iodine on Gd-DTPA enhanced MR arthrography. J Magn Reson Imaging 25, 1219-1225 (2007)
  • Ho LM, Nelson RC, DeLong DM. Determining contrast medium dose and rate on basis of lean body weight: Does this strategy improve patient-to-patient uniformity of hepatic enhancement during multi-detector row CT?. Radiology 243, 431-437 (2007)
  • Holscher T, Sattin JA, Raman R, Wilkening W, Fanale CV, Olson CV, Mettrey RF, Lyden PD. Real-time cerebral angiography: Sensitivity of a new contrast-specific ultrasound technique. Am J Neuroradiol 28, 635-639 (2007)
  • Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 13, 636-641 (2007)
  • Kim K, Huang SW, Ashkenazi S, O'Donnell M, Agarwal A, Kotov NA, Denny MF, Kaplan MJ. Photoacoustic imaging of early inflammatory response using gold nanorods. Appl Phys Lett 90, 223901 (2007)
  • Kramer H, Michaely HJ, Requardt M, Rohrer M, Reeder S, Reiser MF, Schoenberg SO. Effects of injection rate and dose on image quality in time-resolved magnetic resonance angiography (MRA) by using 1.0M contrast agents. Eur Radiol 17, 1394-1402 (2007)
  • Kumar S, Harrison N, Richards-Kortum R, Sokolov K. Plasmonic nanosensors for imaging intracellular biomarkers in live cells. Nano Lett 7, 1338-1343 (2007)
  • Li R, Guo YL, Hua X, He Y, Ding M, Guo AM, Luo MK. Characterization of focal liver lesions: Comparison of pulse-inversion harmonic contrast-enhanced sonography with contrast-enhanced CT. J Clin Ultrasound 35, 109-117 (2007)
  • Mehier-Humbert S, Yan F, Frinking P, Schneider M, Guy RH, Bettinger T. Ultrasound-mediated gene delivery: Influence of contrast agent on transfection. Bioconjug Chem 18, 652-662 (2007)
  • Murase K, Miyazaki S. Error analysis of tumor blood flow measurement using dynamic contrast-enhanced data and model-independent deconvolution analysis. Phys Med Biol 52, 2791-2805 (2007)
  • Nael K, Fenchel M, Krishnam M, Finn JP, Laub G, Ruehm SG. 3.0 Tesla high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) of the pulmonary circulation - Initial experience with a 32-channel phased array coil using a high relaxivity contrast agent. Invest Radiol 42, 392-398 (2007)
  • Norton SJ, Vo-Dinh T. Imaging the distribution of magnetic nanoparticles with ultrasound. IEEE Trans Med Imaging 26, 660-665 (2007)
  • Oude Engberink RD, Van der Pol SMA, Dopp EA, De Vries HE, Blezer ELA. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 243, 467-474 (2007)
  • Peldschus K, Kaul M, Lange C, Nolte-Ernsting C, Adam G, Ittrich H. Magnetic resonance imaging of single SPIO labeled mesenchymal stem cells at 3 Tesla (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 179, 473-479 (2007)
  • Rosen Y, Bloch BN, Lenkinski RE, Greenman RL, Marquis RP, Rofsky NM. 3T MR of the prostate: Reducing susceptibility gradients by inflating the endorectal coil with a barium sulfate suspension. Magn Reson Med 57, 898-904 (2007)
  • Ruan C, Yang SH, Cusi K, Gao F, Clarke GD. Contrast-enhanced first-pass myocardial perfusion magnetic resonance imaging with parallel acquisition at 3.0 Tesla. Invest Radiol 42, 352-360 (2007)
  • Tan WB, Zhang Y. Multi-functional chitosan nanoparticles encapsulating quantum dots and Gd-DTPA as imaging probes for bio-applications. J Nanosci Nanotechnol 7, 2389-2393 (2007)
  • Tanner C, Schnabel JA, Hill DLG, Hawkes DJ, Degenhard A, Leach MO, Hose DR, Hall-Craggs MA, Usiskin SI. Quantitative evaluation of free-form deformation registration for dynamic contrast-enhanced MR mammography. Med Phys 34, 1221-1233 (2007)
  • Williams JB, Ye Q, Hitchens TK, Kaufman CL, Ho C. MRI detection of macrophages labeled using micrometer-sized iron oxide particles. J Magn Reson Imaging 25, 1210-1218 (2007)
  • Wirestam R, Knutsson L, Risberg J, Borjesson S, Larsson EM, Gustafson L, Passant U, Stahlberg F. Attempts to improve absolute quantification of cerebral blood flow in dynamic susceptibility contrast magnetic resonance imaging: A simplified T1-weighted steady-state cerebral blood volume approach. Acta Radiol 48, 550-556 (2007)
  • Wittram C, Yoo AJ. Transient interruption of contrast on CT pulmonary angiography: Proof of mechanism. J Thorac Imag 22, 125-129 (2007)
  • Yoo B, Raam MS, Rosenblum RM, Pagel MD. Enzyme-responsive PARACEST MRI contrast agents: A new biomedical imaging approach for studies of the proteasome. Contrast Media Mol Imaging 2, 189-198 (2007)
  • Yoshifuku S, Chen S, McMahon E, Korinek J, Yoshikawa A, Ochiai I, Sengupta PP, Belohlavek M. Parametric detection and measurement of perfusion defects in attenuated contrast echocardiographic images. J Ultrasound Med 26, 739-748 (2007)
  • Zhao S, Kruse DE, Ferrara KW, Dayton PA. Selective imaging of adherent targeted ultrasound contrast agents. Phys Med Biol 52, 2055-2072 (2007)
  • Zheng JZ, Liu JB, Dunne M, Jaffray DA, Allen C. In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res 24, 1193-1201 (2007)
  • Zierhut ML, Gardner JC, Spilker ME, Sharp JT, Vicini P. Kinetic modeling of contrast-enhanced MRI: An automated technique for assessing inflammation in the rheumatoid arthritis wrist. Ann Biomed Eng 35, 781-795 (2007)
  • Zizka J, Klzo L, Ferda J, Mrklovsky M, Bukac J. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: Comparison of gadoxetic acid and gadobutrol. Eur J Radiol 62, 186-191 (2007)
  • 5. Experimental
  • Arita J, Kokudo N, Zhang KM, Makuuchi M. Three-dimensional visualization of liver segments on contrast-enhanced intraoperative sonography. Am J Roentgenol 188, W464-W466 (2007)
  • Chaubet F, Bertholon I, Serfaty JM, Bazeli R, Alsaid H, Jandrot-Perrus M, Zahir C, Even P, Bachelet L, Touat Z, Lancelot E, Corot C, Canet-Soulas E, Letourneur D. A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media Mol Imaging 2, 178-188 (2007)
  • Dahlstrom N, Persson A, Albiin N, Smedby O, Brismar TB. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Acta Radiol 48, 362-368 (2007)
  • Hirokawa T, Karshafian R, Pavlin CJ, Burns PN. Insonation of the eye in the presence of microbubbles - Preliminary study of the duration and degree of vascular bioeffects - Work in progress. J Ultrasound Med 26, 731-738 (2007)
  • Ittrich H, Lange C, Togel F, Zander AR, Dahnke H, Westenfelder C, Adam G, Nolte-Ernsting C. In vivo magnetic resonance imaging of iron oxide-labeled, arterially-injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney injury: Detection and monitoring at 3T. J Magn Reson Imaging 25, 1179-1191 (2007)
  • Kim EH, Ahn Y, Lee HS. Biomedical applications of superparamagnetic iron oxide nanoparticles encapsulated within chitosan. J Alloys Compounds 434, 633-636 (2007)
  • Kumar A, Bis KG, Shetty A, Vyas A, Anderson A, Balasubramaniam M, O'Neill W, Stein W. Aortic root catheter-directed coronary CT angiography in swine: Coronary enhancement with minimum volume of iodinated contrast material. Am J Roentgenol 188, W415-W422 (2007)
  • Kuribayashi H, Worthington PL, Bradley DP, Checkley DR, Tessier JJ, Waterton JC. Misregistration artifacts in image-derived arterial input function in non-echo-planar imaging-based dynamic contrast-enhanced MRI. J Magn Reson Imaging 25, 1248-1255 (2007)
  • Ludemann L, Schmitt B, Podrabsky P, Schnackenburg B, Bock J, Gutberlet M. Usage of the T1 effect of an iron oxide contrast agent in an animal model to quantify myocardial blood flow by MRI. Eur J Radiol 62, 247-256 (2007)
  • Matschke K, Gerk U, Mrowietz C, Park JW, Jung F. Influence of radiographic contrast media on myocardial oxygen tension: A randomized, NaCl-controlled comparative study of iodixanol versus iomeprol in pigs. Acta Radiol 48, 292-299 (2007)
  • Niermann KJ, Fleischer AC, Huamani J, Yankeelov TE, Kim DW, Wilson WD, Hallahan DE. Measuring tumor perfusion in control and treated murine tumors - Correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26, 749-756 (2007)
  • Stracke CP, Katoh M, Wiethoff AJ, Parsons EC, Spangenberg P, Spuntrup E. Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent. Stroke 38, 1476-1481 (2007)
  • Suzuki Y, Zhang S, Kundu P, Yeung AC, Robbins RC, Yang PC. In vitro comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides. Magn Reson Med 57, 1173-1179 (2007)
  • Wang YL, Ye FR, Jeong EK, Sun Y, Parker DL, Lu ZR. Noninvasive visualization of pharmacokinetics, biodistribution and tumor targeting of poly[N-(2-hydroxypropyl)methacrylamide] in mice using contrast enhanced MRI. Pharm Res 24, 1208-1216 (2007)
  • 6. Applications
  • Bauer JS, Henning TD, Mueller D, Lu Y, Majumdar S, Link TM. Volumetric quantitative CT of the spine and hip derived from contrast-enhanced MDCT: Conversion factors. Am J Roentgenol 188, 1294-1301 (2007)
  • Laurent V, Corby S, Barbary C, Kermarrec E, Beot S, Regent D. New possibilities to study biliary tree and gallbladder: Functional magnetic resonance cholangiography contrast-enhanced with mangafodipir trisodium (Mn DPDP) (French, English Abstract). J Radiol 88, 531-540 (2007)
  • Munoz A, Hinojosa J, Esparza J. Cisternography and ventriculography gadopentate dimeglumine-enhanced MR imaging in pediatric patients: Preliminary report. Am J Neuroradiol 28, 889-894 (2007)
  • Numata K, Oka H, Morimoto M, Sugimori K, Kunisaki R, Nihonmatsu H, Matsuo K, Nagano Y, Nozawa A, Tanaka K. Differential diagnosis of gallbladder diseases with contrast-enhanced harmonic gray scale ultrasonography. J Ultrasound Med 26, 763-774 (2007)
  • Petrou M, Foerster B, Maly PV, Eldevik OP, Leber S, Sundgren PC. Added utility of gadolinium in the magnetic resonance imaging (MRI) workup of seizures in children younger than 2 years. J Child Neurol 22, 200-203 (2007)
  • Rasche V, Binner L, Cavagna F, Hombach V, Kunze M, Spiess J, Stuber M, Merkle N. Whole-heart coronary vein imaging: A comparison between non-contrast-agent- and contrast-agent-enhanced visualization of the coronary venous system. Magn Reson Med 57, 1019-1026 (2007)
  • Setola SV, Catalano O, Sandomenico F, Siani A. Contrast-enhanced sonography of the kidney. Abdom Imaging 32, 21-28 (2007)
  • Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: Case report and implications. Contrast Media Mol Imaging 2, 199-205 (2007)
  • Utz W, Niendorf T, Wassmuth R, Messroghli D, Dietz R, Schulz-Menger J. Contrast-dose relation in first-pass myocardial MR perfusion imaging. J Magn Reson Imaging 25, 1131-1135 (2007)
  • Vogt FM, Herborn CU, Parsons EC, Kroger K, Barkhausen J, Goyen M. Diagnostic performance of contrast-enhanced MR angiography of the aortoiliac arteries with the blood pool agent Vasovist®: Initial results in comparison to intra-arterial DSA (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 179, 412-420 (2007)
  • Wang ZL, Tang J, An LC, Wang W, Luo YK, Li JL, Xu JH. Contrast-enhanced ultrasonography for assessment of tumor vascularity in hepatocellular carcinoma. J Ultrasound Med 26, 757-762 (2007)
  • Wilson SR, Jang HJ, Kim TK, Burns PN. Diagnosis of focal liver masses on ultrasonography: Comparison of unenhanced and contrast-enhanced scans. J Ultrasound Med 26, 775-787 (2007)
  • Wink MH, De La Rosette JJMCH, Laguna P, Lagerveld BW, Wijkstra H. Ultrasonography of renal masses using contrast pulse sequence imaging: A pilot study. J Endourol 21, 466-472 (2007)
  • Molecular Imaging: 7. Carbon
  • Anderson AN, Pavese N, Edison P, Tai YF, Hammers A, Gerhard A, Brooks DJ, Turkheimer FE. A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195. Neuroimage 36, 28-37 (2007)
  • Bartnik BL, Lee SM, Hovda DA, Sutton RL. The fate of glucose during the period of decreased metabolism after fluid percussion injury: A 13C NMR study. J Neurotrauma 24, 1079-1092 (2007)
  • Bhattacharya P, Chekmenev EY, Perman WH, Harris KC, Lin AP, Norton VA, Tan CT, Ross BD, Weitekamp DP. Towards hyperpolarized 13C-succinate imaging of brain cancer. J Magn Reson 186, 150-155 (2007)
  • Boutin H, Chauveau F, Thominiaux C, Gregoire MC, James ML, Trebossen R, Hantraye P, Dolle F, Tavitian B, Kassiou M. 11C-DPA-713: A novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med 48, 573-581 (2007)
  • Cumming P, Moller M, Benda K, Minuzzi L, Jakobsen S, Jensen SB, Pakkenberg B, Stark AK, Gramsbergen JB, Andreasen MF, Olsen AK. A PET study of effects of chronic 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) on serotonin markers in Gottingen minipig brain. Synapse 61, 478-487 (2007)
  • Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M. In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9, 117-125 (2007)
  • Kumar JSD, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(4-(2-methoxyphenyl) piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3, 5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 34, 1050-1060 (2007)
  • Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med 48, 538-546 (2007)
  • Lodi F, Trespidi S, Di Pierro D, Marengo M, Farsad M, Fanti S, Franchi R, Boschi S. A simple Tracerlab module modification for automated on-column [11C]methylation and [11C]carboxylation. Appl Radiat Isot 65, 691-695 (2007)
  • McCann UD, Szabo Z, Vranesic M, Seckin E, Wand G, Duval A, Dannals RF, Ricaurte GA. Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine. Mol Imaging Biol 9, 151-157 (2007)
  • Miller PW, Long NJ, De Mello AJ, Vilar R, Audrain H, Bender D, Passchier J, Gee A. Rapid multiphase carbonylation reactions by using a microtube reactor: Applications in positron emission tomography 11C-radiolabeling. Angew Chem Int Ed 46, 2875-2878 (2007)
  • Moresco RM, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, Carpinelli A, Gobbo C, Bellodi L, Perani D, Fazio F. Fluvoxamine treatment and D2 receptors: A PET study on OCD drug-naive patients. Neuropsychopharmacology 32, 197-205 (2007)
  • Moses-Kolko EL, Price JC, Thase ME, Meltzer CC, Kupfer DJ, Mathis CA, Bogers WD, Berman SR, Houck PR, Schneider TN, Drevets WC. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse 61, 523-530 (2007)
  • Naganawa M, Kimura Y, Mishina M, Manabe Y, Chihara K, Oda K, Ishii K, Ishiwata K. Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging 34, 679-687 (2007)
  • Peng FY, Juhasz C, Bhambhani K, Wu DF, Chugani DC, Chugani HT. Assessment of progression and treatment response of optic pathway glioma with positron emission tomography using α-[11C]methyl-L-tryptophan. Mol Imaging Biol 9, 106-109 (2007)
  • Probst KC, Izquierdo D, Bird JLE, Brichard L, Franck D, Davies JR, Fryer TD, Richards HK, Clark JC, Davenport AP, Weissberg PL, Warburton EA. Strategy for improved [11C]DAA1106 radiosynthesis and in vivo, peripheral benzodiazepine receptor imaging using microPET, evaluation of [11C]DAA1106. Nucl Med Biol 34, 439-446 (2007)
  • Raffel DM, Jung YW, Gildersleeve DL, Sherman PS, Moskwa JJ, Tluczek LJ, Chen W. Radiolabeled phenethylguanidines: Novel imaging agents for cardiac sympathetic neurons and adrenergic tumors. J Med Chem 50, 2078-2088 (2007)
  • Ribeiro MJ, Ricard M, Lievre MA, Bourgeois S, Emond P, Gervais P, Dolle F, Syrota A. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [11C] PE2I in healthy volunteers. Nucl Med Biol 34, 465-470 (2007)
  • Schuitemaker A, Van Berckel BNM, Kropholler MA, Veltman DJ, Scheltens P, Jonker C, Lammertsma AA, Boellaard R. SPM analysis of parametric (R)-[11C]PK11195 binding images: Plasma input versus reference tissue parametric methods. Neuroimage 35, 1473-1479 (2007)
  • Serres S, Bezancon E, Franconi JM, Merle M. Brain pyruvate recycling and peripheral metabolism: An NMR analysis ex vivo of acetate and glucose metabolism in the rat. J Neurochem 101, 1428-1440 (2007)
  • Severance AJ, Milak MS, Kumar JSD, Prabhakaran J, Majo VJ, Simpson NR, Van Heertum RL, Arango V, Mann JJ, Parsey RV. In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter. Eur J Nucl Med Mol Imaging 34, 688-693 (2007)
  • Shetty HU, Zoghbi SS, Liow JS, Ichise M, Hong J, Musachio JL, Halldin C, Seidel J, Innis RB, Pike VW. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C] PE2I. Eur J Nucl Med Mol Imaging 34, 667-678 (2007)
  • Sullivan GM, Parsey RV, Kumar JSD, Arango V, Kassir SA, Huang YY, Simpson NR, Van Heertum RL, Mann JJ. PET imaging of CRF1 with [11C]R121920 and [11C]DMP696: Is the target of sufficient density?. Nucl Med Biol 34, 353-361 (2007)
  • Sun AJ, Sorensen AJ, Karlsson M, Turesson I, Langstrom B, Nilsson P, Cederblad L, Bertling J, Riklund K, Johansson S. 1-[11C]-acetate PET imaging in head and neck cancer - A comparison with 18FDG-PET: Implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging 34, 651-657 (2007)
  • Thominiaux C, Mattner F, Greguric I, Boutin H, Chauveau F, Kuhnast B, Gregoire MC, Loc'h C, Valette H, Bottlaender M, Hantraye P, Tavitian B, Katsifis A, Dolle F. Radiosynthesis of 2-[6-chloro-2-(4-iodophenyl)imidazo [1,2-a]pyridin-3-yl]-N-ethyl-N-[11C]methyl-acetamide, [11C]CLINME, a novel radioligand for imaging the peripheral benzodiazepine receptors with PET. J Label Compound Radiopharm 50, 229-236 (2007)
  • Wyss MT, Ametamey SM, Treyer V, Bettio A, Blagoev M, Kessler LJ, Burger C, Weber B, Schmidt M, Gasparini F, Buck A. Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a β-scintillator. Neuroimage 35, 1086-1092 (2007)
  • Zhang XY, Yasuno F, Zoghbi SS, Liow JS, Hong J, McCarron JA, Pike VW, Innis RB. Quantification of serotonin 5-HT1A receptors in humans with [11C](R)-(-)-RWAY: Radiometabolite(s) likely confound brain measurements. Synapse 61, 469-477 (2007)
  • Zheng QH, Gao MZ, Mock BH, Wang SY, Hara T, Nazih R, Miller MA, Receveur TJ, Lopshire JC, Groh WJ, Zipes DP, Hutchins GD, DeGrado TR. Synthesis and biodistribution of new radiolabeled high-affinity choline transporter inhibitors [11C]hemicholinium-3 and [18F]hemicholinium-3. Bioorg Med Chem Lett 17, 2220-2224 (2007)
  • 8. Fluorine
  • Ahmed N, Langlois R, Rodrigue S, Benard F, Van Lier JE. Automated synthesis of 11β-methoxy-4,16α-[16α-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography. Nucl Med Biol 34, 459-464 (2007)
  • Alauddin MM, Shahinian A, Park R, Tohme M, Fissekis JD, Conti PS. In vivo evaluation of 2′-deoxy-2′-[18F]fluoro-5-iodo-1-β-D-arabinofuranosyluracil ([18F]FIAU) and 2′-deoxy-2′[18F]fluoro-5-ethyl-1-β-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression. Eur J Nucl Med Mol Imaging 34, 822-829 (2007)
  • Aliaga A, Rousseau JA, Cadorette J, Croteau E, Van Lier JE, Lecomte R, Benard F. A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[18F]fluoro-D-glucose in murine models of breast cancer. Mol Imaging Biol 9, 144-150 (2007)
  • Bar-Sever Z, Keidar Z, Ben-Barak A, Bar-Shalom R, Postovsky S, Guralnik L, Ben Arush MW, Israel O. The incremental value of 18FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging 34, 630-637 (2007)
  • Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff ASM, De Geus-Oei LF, Rijnders AJ, Krabbe PFM, Corstens FHM, Van der Meer JWM, Oyen WJG. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 34, 694-703 (2007)
  • Chaise C, Itti E, Petegnief Y, Wirquin E, Copie-Bergman C, Farcet JP, Delfau-Larue MH, Meignan M, Talbot JN, Molinier-Frenkel V. [18F]-Fluoro-2-deoxy-D-glucose positon emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model. Cancer Immunol Immunother 56, 1163-1171 (2007)
  • Chandra R, Oya S, Kung MP, Hou C, Jin LW, Kung HF. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J Med Chem 50, 2415-2423 (2007)
  • Chang CW, Chou TK, Liu RS, Wang SJ, Lin WJ, Chen CH, Wang HE. A robotic synthesis of [18F]fluoromisonidazole ([18F]FMISO). Appl Radiat Isot 65, 682-686 (2007)
  • Cheng DF, Yin DZ, Zhang L, Wang MW, Li GC, Wang YX. Radiosynthesis of 18F-(R8,15,21, L-17)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours. Nucl Med Commun 28, 501-506 (2007)
  • Cheon GJ, Chung HK, Choi JA, Lee SJ, Ahn SH, Lee TS, Choi CW, Lim SM. Cellular metabolic responses of PET radiotracers to 188Re radiation in an MCF7 cell line containing dominant-negative mutant p53. Nucl Med Biol 34, 425-432 (2007)
  • Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18FDG microPET studies in mouse tumor xenografts. J Nucl Med 48, 602-607 (2007)
  • Elmenhorst D, Meyer PT, Matusch A, Winz OH, Zilles K, Bauer A. Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET. Eur J Nucl Med Mol Imaging 34, 1061-1070 (2007)
  • Faust A, Wagner S, Law MP, Hermann S, Schnockel U, Keul P, Schober O, Schafers M, Levkau B, Kopka K. The nonpeptidyl caspase binding radioligand (S)-1-(4-(2-[18F]fluoroethoxy)benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging 51, 67-73 (2007)
  • Glaser M, Arstad E. “Click labeling” with 2-[18F]fluoroethylazide for positron emission tomography. Bioconjug Chem 18, 989-993 (2007)
  • Gordin A, Golz A, Daitzchman M, Keidar Z, Bar-Shalom R, Kuten A, Israel O. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: Diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys 68, 370-376 (2007)
  • Haugbol S, Pinborg LH, Arfan HM, Frokjaer VM, Madsen J, Dyrby TB, Svarer C, Knudsen GM. Reproducibility of 5-HT2A receptor measurement and sample size estimations with [18F] altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging 34, 910-915 (2007)
  • Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC). Appl Radiat Isot 65, 696-700 (2007)
  • Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 48, 746-753 (2007)
  • Klomp D, Van Laarhoven H, Scheenen T, Kamm Y, Heerschap A. Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed 20, 485-492 (2007)
  • Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Tanai K, Arai H. 2-(2-[2-Dimethylaminothiazol-5yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48, 553-561 (2007)
  • Lee SJ, Oh SJ, Chi DY, Kang SH, Kil HS, Kim JS, Moon DH. One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nucl Med Biol 34, 345-351 (2007)
  • Liu HY, Teramoto K, Kawamura K, Oda K, Ishiwata K, Arii S. Evaluation of tumor growth in vivo in a rat model of liver metastasis, using a newly devised index obtained by positron emission tomography with [18F] FDG. J Hepatobiliary Pancreat Surg 14, 276-282 (2007)
  • Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez-Sainz J, Gomez-Rio M, Bellon-Guardia M, Ramos-Font C, Rebollo-Aguirre AC, Cabello-Garcia D, Ferron-Orihuela A. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 34, 859-867 (2007)
  • Makrides V, Bauer R, Weber W, Wester HJ, Fischer S, Hinz R, Huggel K, Opfermann T, Herzau M, Ganapathy V, Verrey F, Brust P. Preferred transport of O-(2-[18F]fluoroethyl)-D-tyrosine-(D-FET) into the porcine brain. Brain Res 1147, 25-33 (2007)
  • Mody RJ, Bui C, Hutchinson RJ, Frey KA, Shulkin BL. Comparison of 18F fluorodeoxyglucose PET with 67Ga scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk Lymphoma 48, 699-707 (2007)
  • Nanni C, Di Leo K, Tonelli R, Pettinato C, Rubello D, Spinelli A, Trespidi S, Ambrosini V, Castellucci P, Farsad M, Franchi R, Pession A, Fanti S. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur J Nucl Med Mol Imaging 34, 755-762 (2007)
  • Nimmagadda S, Mangner TJ, Douglas KA, Muzik O, Shields AF. Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2′-deoxy-2′-18F-fluoro-β-D-arabinofuranosyl)-5-iodouracil in normal dogs. J Nucl Med 48, 655-660 (2007)
  • Partlow KC, Chen JJ, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, Nolta JA, Caruthers SD, Lanza GM, Wickline SA. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 21, 1647-1654 (2007)
  • Piel M, Bauman A, Baum RP, Hohnemann S, Klette I, Wortmann R, Rosch F. Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imaging. Bioorg Med Chem 15, 3171-3175 (2007)
  • Ponomarev V, Doubrovin M, Shavrin A, Serganova I, Beresten T, Ageyeva L, Cai CD, Balatoni J, Alauddin M, Gelovani J. A human-derived reporter gene for noninvasive imaging in humans: Mitochondrial thymidine kinase type 2. J Nucl Med 48, 819-826 (2007)
  • Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB, Matei C, Ling CC, Koutcher JA. In vivo19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res 13, 3738-3747 (2007)
  • Salem N, MacLennan GT, Kuang Y, Anderson PW, Schomisch SJ, Tochkov IA, Tennant BC, Lee ZH. Quantitative evaluation of 2-deoxy-2[18F]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol 9, 135-143 (2007)
  • Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 34, 1003-1011 (2007)
  • Seo JW, Chi DY, Dence CS, Welch MJ, Katzenellenbogen JA. Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor. Nucl Med Biol 34, 383-390 (2007)
  • Sirion U, Kim HJ, Lee JH, Seo JW, Lee BS, Lee SJ, Oh SJ, Chi DY. An efficient 18F labeling method for PET study: Huisgen 1,3-dipolar cycloaddition of bioactive substances and 18F-labeled compounds. Tetrahedron Lett 48, 3953-3957 (2007)
  • Soderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging 34, 1018-1022 (2007)
  • Strauss LG, Klippel S, Pan LY, Schonleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: Which parameters are important with respect to tumour detection?. Eur J Nucl Med Mol Imaging 34, 868-877 (2007)
  • Timmers HJLM, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JWM, Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25, 2262-2269 (2007)
  • Van Dalen JA, Hoffmann AL, Dicken V, Vogel WV, Wiering B, Ruers TJ, Karssemeijer N, Oyen WJG. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun 28, 485-493 (2007)
  • Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R. 18F-choline and/or 11C-acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99, 1415-1420 (2007)
  • Vuong BK, Kiesewetter DO, Lang LX, Ma Y, Eckelman WC, Channing MA. An automated one-step one-pot [18F]FCWAY synthesis: Development and minimization of chemical impurities. Nucl Med Biol 34, 433-438 (2007)
  • Wartski M, Le Stanc E, Gontier E, Vilain D, Banal A, Tainturier C, Pecking AP, Alberini JL. In search of an unknown primary tumour presenting with cervical metastases: Performance of hybrid FDG-PET-CT. Nucl Med Commun 28, 365-371 (2007)
  • Waterhouse RN, Chang RC, Atuehene N, Collier TL. In vitro and in vivo binding of neuroactive steroids to the σ-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse 61, 540-546 (2007)
  • Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, Rummeny E, Siewert JR, Schwaiger M, Stollfuss J. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34, 878-883 (2007)
  • Wu HM, Sui G, Lee CC, Prins ML, Ladno W, Lin HD, Yu AS, Phelps ME, Huang SC. In vivo quantitation of glucose metabolism in mice using small-animal PET and a microfluidic device. J Nucl Med 48, 837-845 (2007)
  • Yapp DTT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fadzli L, Ruth T, Adam MJ, Green D, Gleave M. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int 99, 1154-1160 (2007)
  • Zincirkeser S, Sahin E, Halac M, Sagar S. Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging. J Int Med Res 35, 231-236 (2007)
  • 9. Gallium
  • Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 34, 982-993 (2007)
  • Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48, 508-518 (2007)
  • Mitterhauser M, Toegel S, Wadsak W, Lanzenberger RR, Mien LK, Kuntner C, Wanek T, Eidherr H, Ettlinger DE, Viernstein H, Kluger R, Dudczak R, Kletter K. Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl Med Biol 34, 391-397 (2007)
  • Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, Gishen P. 68Ga-DOTATATE PET in neuroectodermal tumours: First experience. Nucl Med Commun 28, 359-363 (2007)
  • 10. Hydrogen
  • Ajilore O, Haroon E, Kumaran S, Darwin C, Binesh N, Mintz J, Miller J, Thomas MA, Kumar A. Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology 32, 1224-1231 (2007)
  • Bartha R. Effect of signal-to-noise ratio and spectral linewidth on metabolite quantification at 4 T. NMR Biomed 20, 512-521 (2007)
  • Cohen BA, Inglese M, Rusinek H, Babb JS, Grossman RI, Gonen O. Proton MR spectroscopy and MRI-volumetry in mild traumatic brain injury. Am J Neuroradiol 28, 907-913 (2007)
  • Frye MA, Thomas MA, Yue K, Binesh N, Davanzo P, Ventura J, O'Neill J, Guze B, Curran JG, Mintz J. Reduced concentrations of N-acetylaspartate (NAA) and the NAA-creatine ratio in the basal ganglia in bipolar disorder: A study using 3-Tesla proton magnetic resonance spectroscopy. Psychiatr Res Neuroimaging 154, 259-265 (2007)
  • Grande S, Giovannini C, Guidoni L, Luciani AM, Palma A, Rosi A, Sapora O, Viti V. 1H MRS signals from glutathione may act as predictive markers of apoptosis in irradiated tumour cells. Radiat Prot Dosimetry 122, 205-206 (2006)
  • Heijmink SWTPJ, Scheenen TWJ, Futterer JJ, Klomp DWJ, Heesakkers RAM, Hulsbergen-van de Kaa CA, Van Lin ENJT, Heerschap A, Barentsz JO. Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol 42, 420-427 (2007)
  • Jansen JFA, Kooi ME, Kessels AFGH, Nicolay K, Backes WH. Reproducibility of quantitative cerebral T2 relaxometry, diffusion tensor imaging, and 1H magnetic resonance spectroscopy at 3.0 Tesla. Invest Radiol 42, 327-337 (2007)
  • Mayer D, Zahr NM, Sullivan EV, Pfefferbaum A. In vivo metabolite differences between the basal ganglia and cerebellum of the rat brain detected with proton MRS at 3T. Psychiatr Res Neuroimaging 154, 267-273 (2007)
  • Nakae I, Mitsunami K, Matsuo S, Horie M. Creatine depletion and altered fatty acid metabolism in diseased human hearts: Clinical investigation using 1H magnetic resonance spectroscopy and 123I BMIPP myocardial scintigraphy. Acta Radiol 48, 436-443 (2007)
  • Nakagawa Y, Hattori M, Harada K, Shirase R, Bando M, Okana G. Age-related changes in intramyocellular lipid in humans by in vivo1H-MR spectroscopy. Gerontology 53, 218-223 (2007)
  • Petrou M, Sundgren PC, Pang YX, Rohrer S, Foerster B, Chenevert TL. Manually adjusted versus vendor-preset definition of metabolite boundaries: Impact on proton metabolite ratios. Acad Radiol 14, 340-343 (2007)
  • Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, Rae C, Green K, Wilcken B, Christodoulou J. The effects of large neutral amino acid supplements in PKU: An MRS and neuropsychological study. Mol Genet Metab 91, 48-54 (2007)
  • Tsai SY, Posse S, Lin YR, Ko CW, Otazo R, Chung HW, Lin FH. Fast mapping of the T2 relaxation time of cerebral metabolites using proton echo-planar spectroscopic imaging (PEPSI). Magn Reson Med 57, 859-865 (2007)
  • Wootton-Gorges SL, Buonocore MH, Kuppermann N, Marcin JP, Barnes PD, Neely Ek, DiCarlo J, McCarthy T, Glaser NS. Cerebral proton magnetic resonance spectroscopy in children with diabetic ketoacidosis. Am J Neuroradiol 28, 895-899 (2007)
  • Yokota H, Guo JF, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by in vitro1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J Magn Reson Imaging 25, 992-999 (2007)
  • 11. Indium
  • Caveliers V, De Keulenaer G, Everaert H, Van Riet I, Van Camp G, Verheye S, Roland J, Schoors D, Franken PR, Schots R. In vivo visualization of 111In labeled CD133+ peripheral blood stem cells after intracoronary administration in patients with chronic ischemic heart disease. Q J Nucl Med Mol Imaging 51, 61-66 (2007)
  • Holstensson M, Hindorf C, Ljungberg M, Partridge M, Flux GD. Optimization of energy-window settings for scatter correction in quantitative 111In imaging: Comparison of measurements and Monte Carlo simulations. Cancer Biother Radiopharm 22, 136-142 (2007)
  • Jang BS, Lim E, Park SH, Shin IS, Danthi N, Hwang IS, Le N, Yu S, Xie JW, Li KCP, Carrasquillo JA, Paik CH. Radiolabeled high affinity peptidomimetic antagonist selectively targets αvβ3 receptor-positive tumor in mice. Nucl Med Biol 34, 363-370 (2007)
  • Nowak B, Weber C, Schober A, Zeiffer U, Liehn EA, Von Hundelshausen P, Reinartz P, Schaefer WM, Buell U. Indium-111 oxine labelling affects the cellular integrity of haematopoietic progenitor cells. Eur J Nucl Med Mol Imaging 34, 715-721 (2007)
  • 12. Iodine
  • Akgun E, Portoghese PS, Sajjad M, Nabi HA. Synthesis and 124I-labeling of m-iodophenylpyrrolomorphinan as a potential PET imaging agent for δ opioid (DOP) receptors. J Label Compound Radiopharm 50, 165-170 (2007)
  • Bauwens M, Lahoutte T, Kersemans K, Caveliers V, Bossuyt A, Mertens J. D-and L-[123I]-2-I-phenylalanine show a long tumour retention compared with D- and L-[123I]-2-I-tyrosine in R1M rhabdomyosarcoma tumour-bearing Wag/Rij rats. Contrast Media Mol Imaging 2, 172-177 (2007)
  • Blanckaert P, Burvenich I, Devos F, Slegers G. Synthesis and in vivo evaluation in mice of (123I)-(4-fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl) methanone as a potential SPECT-tracer for the serotonin 5-HT2A receptor. J Label Compound Radiopharm 50, 183-188 (2007)
  • Broisat A, Riou LM, Ardisson V, Boturyn D, Dumy P, Fagret D, Ghezzi C. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p. Eur J Nucl Med Mol Imaging 34, 830-840 (2007)
  • Fernandes C, Oliveira C, Gano L, Bourkoula A, Pirmettis I, Santos I. Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer. Bioorg Med Chem 15, 3974-3980 (2007)
  • Keyaerts M, Lahoutte T, Neyns B, Caveliers V, Vanhove C, Everaert H, Kersemans K, Franken PR, Mertens J, Bossuyt A. 123I-2-iodo-tyrosine, a new tumour imaging agent: Human biodistribution, dosimetry and initial clinical evaluation in glioma patients. Eur J Nucl Med Mol Imaging 34, 994-1002 (2007)
  • Koch W, Hornung J, Hamann C, Popperl G, Tatsch K. Equipment-independent reference values for dopamine transporter imaging with 123I-FP-CIT. Nuklearmedizin 46, 107-111 (2007)
  • Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, Dyomina E, Burnazi E, Finn RD, Doubrovin M, Blasberg RG. Imaging hNET reporter gene expression with 124I-MIBG. J Nucl Med 48, 827-836 (2007)
  • Qu WC, Kung MP, Hou C, Benedum TE, Kung HF. Novel styrylpyridines as probes for SPECT imaging of amyloid plaques. J Med Chem 50, 2157-2165 (2007)
  • Tang Y, Yang SX, Gariepy J, Scollard DA, Reilly RM. Construction and evaluation of the tumour imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49. Bioconjug Chem 18, 677-684 (2007)
  • Urhan M, Dadparvar S, Mavi A, Houseni M, Chamroonrat W, Alavi A, Mandel SJ. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: A comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 34, 1012-1017 (2007)
  • Vaidyanathan G, Affleck DJ, Alston KL, Zalutsky MR. A tin precursor for the synthesis of no-carrier-added [I]MIBG and [211At]MABG. J Label Compound Radiopharm 50, 177-182 (2007)
  • Wu CY, Wei JJ, Gao KQ, Wang YM. Dibenzothiazoles as novel amyloid-imaging agents. Bioorg Med Chem 15, 2789-2796 (2007)
  • Yang YK, Yao WJ, Yeh TL, Lee IH, Chen KC, Lu RB. Association between serotonin transporter availability and hostility scores in healthy volunteers - A single photon emission computed tomography study with [123I] ADAM. Psychiatr Res Neuroimaging 154, 281-284 (2007)
  • 13. Phosphorus
  • Thelwall PE. Detection of 17O-tagged phosphate by 31P MRS: A method with potential for in vivo studies of phosphorus metabolism. Magn Reson Med 57, 1168-1172 (2007)
  • 14. Technetium
  • Decristoforo C, Santos I, Pietzsch HJ, Kuenstler JU, Duatti A, Smith CJ, Rey A, Alberto R, Von Guggenberg E, Haubner R. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores. Q J Nucl Med Mol Imaging 51, 33-41 (2007)
  • Engfeldt T, Orlova A, Tran T, Bruskin A, Widstrom C, Karlstrom AE, Tolmachev V. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34, 722-733 (2007)
  • Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning EP, De Jong M. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo99mTc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm 22, 40-49 (2007)
  • Garcia Garayoa E, Schweinsberg C, Maes V, Ruegg D, Blanc A, Blauenstein P, Tourwe DA, Beck-Sickinger AG, Schubiger PA. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Q J Nucl Med Mol Imaging 51, 42-50 (2007)
  • Hwang do W, Kang JH, Chang YS, Jeong JN, Chung JK, Lee MC, Kim S, Lee DS. Development of a dual membrane protein reporter system using sodium iodide symporter and mutant dopamine D2 receptor transgenes. J Nucl Med 48, 588-595 (2007)
  • Ishino S, Kuge Y, Takai N, Tamaki N, Strauss HW, Blankenberg FG, Shiomi M, Saji H. 99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: Imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Eur J Nucl Med Mol Imaging 34, 889-899 (2007)
  • Kurtulmus N, Turkmen C, Yarman S, Tokmak H, Mudun A. The value of 99mTc tetrofosmin in the imaging of pituitary adenomas. J Endocrinol Invest 30, 86-90 (2007)
  • Waehrens LN, Rasmussen JT, Heegaard CW, Falborg L. Preparation and in vitro evaluation of 99mTc-labelled bovine lactadherin as a novel radioligand for apoptosis detection. J Label Compound Radiopharm 50, 211-217 (2007)
  • 15. Others
  • Biddlecombe GB, Rogers BE, De Visser M, Parry JJ, De Jong M, Erion JL, Lewis JS. Molecular imaging of gastrin-releasing peptide receptor-positive tumours in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). Bioconjug Chem 18, 724-730 (2007)
  • Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging. Eur J Nucl Med Mol Imaging 34, 841-849 (2007)
  • Cai WB, Chen K, He LN, Cao QH, Koong A, Chen XY. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34, 850-858 (2007)
  • Chen AP, Cunningham CH, Ozturk-Isik E, Xu D, Hurd RE, Kelley DAC, Pauly JM, Kurhanewicz J, Nelson SJ, Vigneron DB. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging 25, 1288-1292 (2007)
  • Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW, Ting G. Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 34, 415-423 (2007)
  • Cheng Z, Xiong ZM, Subbarayan M, Chen XY, Gambhir SS. 64Cu-Labeled α-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 18, 765-772 (2007)
  • Hastings DL, Reader AJ, Julyan PJ, Zweit J, Jeavons AP, Jones T. Performance characteristics of a small animal PET camera for molecular imaging. Nucl Instrum Methods Phys Res A 573, 80-83 (2007)
  • Hayek A, Ercelen S, Zhang X, Bolze F, Nicoud JF, Schaub E, Baldeck PL, Mely Y. Conjugation of a new two-photon fluorophore to poly(ethylenimine) for gene delivery imaging. Bioconjug Chem 18, 844-851 (2007)
  • Hu JN, Yang SL, Xuan Y, Jiang Q, Yang YH, Haacke EM. Simultaneous detection of resolved glutamate, glutamine, and γ-aminobutyric acid at 4 T. J Magn Reson 185, 204-213 (2007)
  • Kershaw J, Nakamura K, Kondoh Y, Wakai A, Suzuki N, Kanno I. Confirming the existence of five peaks in 129Xe rat head spectra. Magn Reson Med 57, 791-797 (2007)
  • Kim HM, Fang XZ, Yang PR, Yi JS, Ko YG, Piao MJ, Chung YD, Park YW, Jeon SJ, Cho BR. Design of molecular two-photon probes for in vivo imaging. 2H-benzo[h]chromene-2-one derivatives. Tetrahedron Lett 48, 2791-2795 (2007)
  • Niu G, Xiong ZM, Cheng Z, Cai WB, Gambhir SS, Xing L, Chen XY. In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol Imaging Biol 9, 126-134 (2007)
  • Poullet JB, Sima DM, Simonetti AW, De Neuter B, Vanhamme L, Lemmerling P, Van Huffel S. An automated quantitation of short echo time MRS spectra in an open source software environment: AQSES. NMR Biomed 20, 493-504 (2007)
  • Roberti MJ, Bertoncini CW, Klement R, Jares-Erijman EA, Jovin TM. Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged α-synuclein. Nat Methods 4, 345-351 (2007)
  • Von Wallbrunn A, Holtke C, Zuhlsdorf M, Heindel W, Schafers M, Bremer C. In vivo imaging of integrin αvβ3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging 34, 745-754 (2007)
  • Woodward JD, Kennel SJ, Mirzadeh S, Dai S, Wall JS, Richey T, Avenell J, Rondinone AJ. In vivo SPECT/CT imaging and biodistribution using radioactive (CdTe)-125mTe/ZnS nanoparticles. Nanotechnology 18, 175103 (2007)
Get PDF (162K)